ID: ALA3143969

Max Phase: Preclinical

Molecular Formula: C9H11BrClN3O4

Molecular Weight: 340.56

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1nc(=O)n([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2Cl)cc1Br

Standard InChI:  InChI=1S/C9H11BrClN3O4/c10-3-1-14(9(17)13-7(3)12)8-5(11)6(16)4(2-15)18-8/h1,4-6,8,15-16H,2H2,(H2,12,13,17)/t4-,5+,6-,8-/m1/s1

Standard InChI Key:  PPXUQXLEOOYXNC-BYPJNBLXSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 340.56

Molecular Weight (Monoisotopic): 338.9621

AlogP: -0.55

#Rotatable Bonds: 2

Polar Surface Area: 110.60

Molecular Species: NEUTRAL

HBA: 7

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.96

CX Basic pKa:

CX LogP: -0.62

CX LogD: -0.62

Aromatic Rings: 1

Heavy Atoms: 18

QED Weighted: 0.62

Np Likeness Score: 0.98

References

1. Watanabe KA, Su TL, Klein RS, Chu CK, Matsuda A, Chun MW, Lopez C, Fox JJ..  (1983)  Nucleosides. 123. Synthesis of antiviral nucleosides: 5-substituted 1-(2-deoxy-2-halogeno-beta-D-arabinofuranosyl)cytosines and -uracils. Some structure-activity relationships.,  26  (2): [PMID:6298422] [10.1021/jm00356a007]

Source

Source(1):

• Scientific Literature